Aligos Therapeutics, Inc.
ALGS
$9.32
-$0.45-4.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.86M | 43.09M | -82.15M | -19.26M | 5.06M |
| Total Depreciation and Amortization | 259.00K | 194.00K | 671.00K | 667.00K | 256.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -830.00K | -60.36M | 63.47M | 1.67M | -28.92M |
| Change in Net Operating Assets | 930.00K | -3.84M | -390.00K | -3.18M | 4.11M |
| Cash from Operations | -15.50M | -20.91M | -18.40M | -20.10M | -19.49M |
| Capital Expenditure | -109.00K | -43.00K | -28.00K | -26.00K | -7.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.31M | -44.02M | 20.00M | 10.42M | 40.00M |
| Cash from Investing | -39.42M | -44.07M | 19.97M | 10.40M | 39.99M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.00K | -- | -43.00K | -5.00K | -16.00K |
| Issuance of Common Stock | -- | 101.74M | 140.00K | 1.00K | 297.00K |
| Repurchase of Common Stock | -176.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -177.00K | 101.74M | 97.00K | -4.00K | 281.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.10M | 36.77M | 1.67M | -9.71M | 20.78M |